An Adaptive Open-label Multicentre Phase 1/2 Trial, to Determine the Recommended Phase 2 Dose of CCTx-001, and to Assess Safety, Tolerability, and Clinical Activity in Patients With Relapsed/Refractory Acute Myeloid Leukaemia

Conditions: Acute Myeloid Leukemia, in Relapse; Acute Myeloid Leukemia Refractory Interventions: Genetic: CCTx-001 Sponsors: Advesya SAS Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials